{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1826.2","upperLimit":"2603.7","value":"2180.5"}]}],"title":"Anti-HPV Type 6 (n=109)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1852.5","upperLimit":"2681.3","value":"2228.7"}]}],"title":"Anti-HPV Type 11 (n=109)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6795.7","upperLimit":"9385.6","value":"7986.3"}]}],"title":"Anti-HPV Type 16 (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2049.4","upperLimit":"2808.1","value":"2399.0"}]}],"title":"Anti-HPV Type 18 (n=138)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1263.9","upperLimit":"1691.5","value":"1462.2"}]}],"title":"Anti-HPV Type 31 (n=131)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1466.7","upperLimit":"1991.2","value":"1709.0"}]}],"title":"Anti-HPV Type 33 (n=137)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"277.2","upperLimit":"376.5","value":"323.0"}]}],"title":"Anti-HPV Type 45 (n=144)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"907.2","upperLimit":"1281.2","value":"1078.1"}]}],"title":"Anti-HPV Type 52 (n=131)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1530.5","upperLimit":"2121.2","value":"1801.8"}]}],"title":"Anti-HPV Type 58 (n=129)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. This outcome measure applied to Cohort 1 participants only.","dispersionType":"95% Confidence Interval","groups":[{"description":"V503 mid-dose 0.5 mL injection in a 3-dose regimen in the Base Study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.","id":"OG000","title":"Extension Study: Mid-dose V503 (Cohort 1)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants in Cohort 1 who received all 3 vaccinations of mid-dose V503 in the Base Study, were seronegative at Day 1 and PCR negative from Day 1 to Month 7 for the relevant HPV types, had no other violation that could interfere with evaluation of immune response, and provided post-dose 4 serum.","reportingStatus":"POSTED","timeFrame":"Month 60 + 1 week: Day 7 postdose 4 in the Extension Study (Cohort 1)","title":"Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58 at Day 7 Postdose 4","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"milli Merck U/mL"}